Top

Published in:

01-12-2020 | Melanoma | ASO Author Reflections

ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma

Authors: Michael J. Carr, MD, MS, Hidde M. Kroon, MD, PhD, Jonathan S. Zager, MD

Published in: Annals of Surgical Oncology | Issue 13/2020

Excerpt

Since its introduction in the early 1990s, isolated limb infusion (ILI) has delivered high-dose chemotherapy to extremities harboring unresectable in-transit melanoma, without the associated morbidity of maximally invasive surgery in isolated limb perfusion or the toxicity of fully systemic treatments. Single- and multi-institutional large cohort series of ILI have demonstrated overall response (OR) rates of 59–84% and complete response (CR) rates of 26–38%.1^,2 Moreover, a recent international multi-institutional effort demonstrated similar OR and CR rates. After a median follow-up of 47 months, median overall survival was 75 months for those who achieved a CR to ILI.3 …

Available only for authorised users

O’Donoghue C, Perez MC, Mullinax JE, et al. Isolated limb infusion: a single-center experience with over 200 infusions. Ann Surg Oncol. 2017;24:3842–9. https://doi.org/10.1245/s10434-017-6107-9.CrossRefPubMed

Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003–13. https://doi.org/10.1245/s10434-008-9954-6.CrossRefPubMed

Miura JT, Kroon HM, Beasley GM, et al. Long–term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: an international multicenter analysis. Ann Surg Oncol. 2019;26:2486–94. https://doi.org/10.1245/s10434-019-07288-w.CrossRefPubMed

Carr MJ, Sun J, Kroon HM, et al. Oncologic outcomes after isolated limb infusion for advanced melanoma: an international comparison of the procedure and outcomes between the United States and Australia. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-09051-y.

Muilenburg, DJ, Beasley, GM, Thompson, ZJ, et al. Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. 2015;22:482–8. https://doi.org/10.1245/s10434-014-4072-0.CrossRefPubMed

Title: ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma
Authors: Michael J. Carr, MD, MS
Hidde M. Kroon, MD, PhD
Jonathan S. Zager, MD
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Systemic Therapy
Published in: Annals of Surgical Oncology / Issue 13/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-09113-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2020

Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis

Impact of Mucin Cellularity and Distribution on Survival in Newly Diagnosed Patients with Low-Grade Appendiceal Mucinous Neoplasm Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

ASO Author Reflections: To Redo or Not to Redo, That is the Question: Assessing the Slings and Arrows of Repeat CRS/HIPEC in Patients with Recurrent or Progressive Peritoneal Carcinomatosis

Robotic Major Hepatectomy: An Institutional Experience and Clinical Outcomes

A Novel Machine-Learning Approach to Predict Recurrence After Resection of Colorectal Liver Metastases

ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies